Today we announced to the market that Jenn Chow has given notice of her resignation as Managing Director and Chief Executive Officer of the Company. It is expected that Jenn will leave the company later this month.
The Board is taking the opportunity refocus the Company's management in Australia, with further announcements on this expected in the very near term.
I want to reassure everyone our programs are on track and we remain enthusiastic about the technology platforms – including the CDH 17 program from University of Pennsylvania which we look forward to providing updates on soon.
As a result of the collective efforts of Jenn and the team, the Company has a strong foundation of cell therapy assets that positions it well for ongoing clinical development.
The Board acknowledges the major contributions made by Jenn and wishes her well in all future endeavours.
Regards
Paul Hopper
Executive Chairman
- Forums
- ASX - By Stock
- CHM
- New email reg. JC
New email reg. JC
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
NEWS
Antler Copper Project hits major permitting milestone – air quality permit advances to final review
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable